ORIC — ORIC Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $619.18m
- $411.00m
- 31
- 21
- 78
- 39
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.76 | ||
| Price to Tang. Book | 2.76 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -47.84% | ||
| Return on Equity | -45.11% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.
Directors
- Richard Heyman NEC (63)
- Jacob Chacko PRE (42)
- Dominic Piscitelli CFO (47)
- Pratik Multani OTH (54)
- Steven Hoerter DRC (50)
- Angie You DRC (46)
- Mardi Dier IND (57)
- Lori Kunkel IND (63)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 29th, 2014
- Public Since
- April 24th, 2020
- No. of Shareholders
- 43
- No. of Employees
- 100
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 67,375,847
- Address
- 240 E. Grand Ave, 2nd Floor, SOUTH SAN FRANCISCO, 94080
- Web
- http://oricpharma.com/
- Phone
- +1 6503885600
- Auditors
- KPMG LLP
Upcoming Events for ORIC
Oric Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2024 Oric Pharmaceuticals Inc Earnings Release
Similar to ORIC
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the ORIC Pharmaceuticals share price?
As of Today at 19:16 UTC, shares in ORIC Pharmaceuticals are trading at $9.19. This share price information is delayed by 15 minutes.
How has the ORIC Pharmaceuticals share price performed this year?
Shares in ORIC Pharmaceuticals last closed at $9.19 and the price had moved by +73.4% over the past 365 days. In terms of relative price strength the ORIC Pharmaceuticals share price has outperformed the S&P500 Index by +44.29% over the past year.
What are the analyst and broker recommendations for ORIC Pharmaceuticals?
The overall consensus recommendation for ORIC Pharmaceuticals is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the ORIC Pharmaceuticals dividend yield?
ORIC Pharmaceuticals does not currently pay a dividend.
Does ORIC Pharmaceuticals pay a dividend?
ORIC Pharmaceuticals does not currently pay a dividend.
When does ORIC Pharmaceuticals next pay dividends?
ORIC Pharmaceuticals does not currently pay a dividend.
How do I buy ORIC Pharmaceuticals shares?
To buy shares in ORIC Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of ORIC Pharmaceuticals?
As of the previous close price of $9.19, shares in ORIC Pharmaceuticals had a market capitalisation of $619.18m.
Where are ORIC Pharmaceuticals shares listed?
Here are the trading details for ORIC Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ORIC
What kind of share is ORIC Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum ORIC Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a ORIC Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in ORIC Pharmaceuticals is $19.14. That is 108.27% above the last closing price of $9.19.
Analysts covering ORIC Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.83 for the next financial year.
What is the trend in the ORIC Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ORIC Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +37.85%.
As of the last closing price of $9.19, shares in ORIC Pharmaceuticals were trading 0% matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the ORIC Pharmaceuticals PE Ratio?
The ORIC Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $9.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of ORIC Pharmaceuticals?
ORIC Pharmaceuticals' management team is headed by:
- Richard Heyman - NEC
- Jacob Chacko - PRE
- Dominic Piscitelli - CFO
- Pratik Multani - OTH
- Steven Hoerter - DRC
- Angie You - DRC
- Mardi Dier - IND
- Lori Kunkel - IND